Isatineoxime derivatives, their preparation and use
    1.
    发明授权
    Isatineoxime derivatives, their preparation and use 失效
    异恶嗪衍生物,其制备和用途

    公开(公告)号:US5436250A

    公开(公告)日:1995-07-25

    申请号:US088328

    申请日:1993-07-07

    摘要: A compound having the formula ##STR1## wherein R.sup.4 and R.sup.5 independently are hydrogen, halogen, CF.sub.3, CN, NO.sub.2 or SO.sub.2 NR.sup.1 R.sup.2 whereinR.sup.1 is hydrogen or C.sub.1-6 -alkyl which may be straight, branched or cyclic,R.sup.2 is hydrogen or C.sub.1-6 -alkyl which may be straight, branched or cyclic, or wherein R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --, wherein A is O, S, CH.sub.2 or NR.sup.I, wherein R.sup.I is H, C.sub.1-6 -alkyl which may be straight, branched or cyclic, n is 0, 1, 2, 3, 4, 5 and m is 0, 1, 2, 3, 4, 5;R.sup.II is hydrogen, benzyl, (C.dbd.O)CF.sub.3, C.sub.1-6 -carboxylic acid acyl, C.sub.1-6 -alkoxy which may be branched or cyclic, or C.sub.1-6 -alkyl which may be straight, branched or cyclic, CH.sub.2 CO.sub.2 R.sup.VI wherein R.sup.VI is hydrogen or C.sub.1-6 -alkyl which may be straight or branched;and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.

    摘要翻译: 具有式“IMAGE”的化合物,其中R4和R5独立地是氢,卤素,CF3,CN,NO2或SO2NR1R2,其中R1是氢或可以是直链,支链或环状的C1-6烷基,R2是氢或C1- 其可以是直链,支链或环状的,或其中R 1和R 2一起表示 - (CH 2)n -A(CH 2)m - ,其中A是O,S,CH 2或NRI,其中R 1是H,C 1-6 - 烷基,其可以是直链,支链或环状的,n为0,1,2,3,4,5,m为0,1,2,3,4,5; RII是氢,苄基,(C = O)CF 3,C 1-6 - 羧酸酰基,可以是支链或环状的C 1-6 - 烷氧基或可以是直链,支链或环状的C 1-6 - 烷基,CH 2 CO 2 RVI,其中 RVI是氢或可以是直链或支链的C1-6烷基; 以及治疗对谷氨酸和天冬氨酸受体的阻断作用的哺乳动物(包括人)的病症的方法。

    Isatinoxime derivatives, their preparation and use
    2.
    发明授权
    Isatinoxime derivatives, their preparation and use 失效
    伊马替尼衍生物,其制备和用途

    公开(公告)号:US5242918A

    公开(公告)日:1993-09-07

    申请号:US936579

    申请日:1992-08-27

    摘要: A compound having the formula ##STR1## wherein R.sup.4 and R.sup.5 independently are hydrogen, halogen, CF.sub.3, CN, NO.sub.2 or SO.sub.2 NR.sup.1 R.sup.2 whereinR.sup.1 is hydrogen or straight, C.sub.1-6 -alkyl which may be branched or cyclic,R.sup.2 is hydrogen or straight, C.sub.1-6 -alkyl which may be branched or cyclic,or wherein R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --, wherein A is O, S, CH.sub.2 or NR.sup.I, wherein R.sup.I is H, C.sub.1-6 -alkyl which may be straight, branched or cyclic, n is 0, 1, 2, 3, 4, 5 and m is 0, 1, 2, 3, 4, 5;Q is NOH or O;Z=O, S, N--R.sup.II, ##STR2## wherein R.sup.II, R.sup.III, R.sup.IV and R.sup.V independently are hydrogen, benzyl, C.sub.1-6 carboxylic acid-acyl, C.sub.1-6 -alkoxy which may be branched or cyclic, or C.sub.1-6 -alkyl which may be branched or cyclic;X is --(CH.sub.2).sub.o -- wherein o is 0, 1, 2, or 3;Y is --(CH.sub.2).sub.p -- wherein p is 0, 1, 2 or 3;.alpha. and .beta. indicate attachment points,and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.

    摘要翻译: 具有式“IMAGE”的化合物,其中R 4和R 5独立地是氢,卤素,CF 3,CN,NO 2或SO 2 NR 1 R 2,其中R 1是氢或直链,可以是支链或环状的C 1-6 - 烷基,R 2是氢或直链, 可以是支链或环状的C 1-6 - 烷基,或其中R 1和R 2一起表示 - (CH 2)nA-(CH 2)m - ,其中A是O,S,CH 2或NRI,其中R 1是H,C 1-6 - 烷基,其可以是直链,支链或环状的,n为0,1,2,3,4,5,m为0,1,2,3,4,5; Q是NOH或O; Z = O,S,N-RII,其中RII,RIII,RIV和RV独立地是氢,苄基,C1-6羧酸 - 酰基,可以是支链或环状的C1-6 - 烷氧基或C1-6 可以是支链或环状的 - 烷基; X是 - (CH 2)o - ,其中o是0,1,2或3; Y是 - (CH 2)p - ,其中p是0,1,2或3; α和β表示连接点,以及一种治疗对谷氨酸和天冬氨酸受体的封闭有反应的哺乳动物(包括人)的病症的方法。

    Indole-2,3-dione-3-oxime derivatives
    3.
    发明授权
    Indole-2,3-dione-3-oxime derivatives 失效
    吲哚-2,3-二酮-3-肟衍生物

    公开(公告)号:US6124285A

    公开(公告)日:2000-09-26

    申请号:US77554

    申请日:1998-06-01

    CPC分类号: C07D471/04 C07D487/04

    摘要: The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising the effect of excitatory amino acids, such as glutamate. More specifically the novel indole-2,3-dione-3-oxime derivatives of the invention may be described by general formula (I), wherein R.sup.3 represents "Het", or a group of formula (II), wherein "Het" represents a saturated or unsaturated, 4 to 7 membered, monocyclic, heterocyclic ring, at least one of R.sup.31, R.sup.32, and R.sup.33 independendy represents hydrogen, alkyl, or hydroxyalkyl, and at least one of R.sup.31, R.sup.32, and R.sup.33 independently represents (CH.sub.2).sub.n R.sup.34 ; wherein R.sup.34 represents hydroxy, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, cycloalkyl-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, CONR.sup.35 R.sup.36, or "Het"; wherein n is 0, 1, 2, or 3; and R.sup.5 represents phenyl, naphthyl, thienyl, or pyridyl, all of which may be substituted. "A" represents a ring of five to seven atoms fused with the benzo ring at the positions marked "a" and "b", and formed by the following bivalent radicals: a-NR.sup.6 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --NR.sup.6 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --NR.sup.6 -b; a-NR.sup.6 --CH.sub.2 --CH.sub.2 --H.sub.2 -b; a-CH.sub.2 --NR.sup.6 --CH.sub.2 --CH.sub.2 -b; a--CH.sub.2 --CH.sub.2 --NR.sup.6 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.6 -b; a-NR.sup.6 --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --NR.sup.6 --CH.sub.2 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --NR.sup.6 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.6 --CH.sub.2 -b; or a-CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.6 -b; wherein R.sup.6 represents hydrogen, alkyl or CH.sub.2 CH.sub.2 OH; or a pharmaceutically acceptable salt thereof.

    摘要翻译: PCT No.PCT / DK97 / 00418 Sec。 371日期1998年6月1日 102(e)日期1998年6月1日PCT 1997年10月1日PCT PCT。 公开号WO98 / 14447 日期:1998年4月9日本发明涉及能够拮抗兴奋性氨基酸如谷氨酸的作用的新的吲哚-2,3-二酮-3-肟衍生物。 更具体地,本发明的新的吲哚-2,3-二酮-3-肟衍生物可以由通式(I)描述,其中R 3表示“Het”,或式(II)的基团,其中“Het”表示 饱和或不饱和的4至7元单环杂环,R 31,R 32和R 33独立的至少一个表示氢,烷基或羟基烷基,并且R 31,R 32和R 33中的至少一个独立地表示(CH 2) nR34; 其中R34表示羟基,羧基,烷氧基羰基,烯氧基羰基,炔氧基羰基,环烷氧基羰基,环烷基 - 烷氧基羰基,芳氧基羰基,芳烷氧羰基,CONR35R36或“Het”。 其中n为0,1,2或3; 并且R 5表示苯基,萘基,噻吩基或吡啶基,它们都可以被取代。 “A”表示在标记为“a”和“b”的位置与苯并环稠合的5至7个原子的环,由以下二价基团形成:a-NR6-CH2-CH2-b; a-CH2-NR6-CH2-b; a-CH2-CH2-NR6-b; a-NR6-CH2-CH2-H2-b; a-CH2-NR6-CH2-CH2-b; a-CH2-CH2-NR6-CH2-b; a-CH2-CH2-CH2-NR6-b; a-NR6-CH2-CH2-CH2-CH2-b; a-CH 2 -NR 6 -CH 2 -CH 2 -CH 2 -B; a-CH2-CH2-NR6-CH2-CH2-b; a-CH2-CH2-CH2-NR6-CH2-b; 或a-CH2-CH2-CH2-CH2-NR6-b; 其中R6表示氢,烷基或CH2CH2OH; 或其药学上可接受的盐。

    Indole-2,3-dione-3-oxime derivatives
    4.
    再颁专利
    Indole-2,3-dione-3-oxime derivatives 失效
    吲哚-2,3-二酮-3-肟衍生物

    公开(公告)号:USRE38200E1

    公开(公告)日:2003-07-22

    申请号:US09956892

    申请日:2001-09-21

    IPC分类号: A61K315375

    CPC分类号: C07D471/04 C07D487/04

    摘要: The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising the effect of excitatory amino acids, such as glutamate. More specifically the novel indole-2,3-dione-3-oxime derivatives of the invention may be described by general formula (I), wherein R3 represents “Het”, or a group of formula (II), wherein “Het” represents a saturated or unsaturated, 4 to 7 membered, monocyclic, heterocyclic ring, at least one of R31, R32, and R33 independendy represents hydrogen, alkyl, or hydroxyalkyl, and at least one of R31, R32, and R33 independently represents (CH2)nR34; wherein R34 represents hydroxy, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, cycloalkylalkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, CONR35R36, or “Het”; wherein n is 0, 1, 2, or 3; and R5 represents phenyl, naphthyl, thienyl, or pyridyl, all of which may be substituted. “A” represents a ring of five to seven atoms fused with the benzo ring at the positions marked “a” and “b”, and formed by the following bivalent radicals: a-NR6—CH2—CH2-b; a-CH2—NR6—CH2-b; a-CH2—CH2—NR6-b; a-NR6—CH2—CH2—H2-b; a-CH2—NR6—CH2—CH2-b; a—CH2—CH2—NR6—CH2-b; a-CH2—CH2—CH2—NR6-b; a-NR6—CH2—CH2—CH2—CH2-b; a-CH2—NR6—CH2—CH2—CH2-b; a-CH2—CH2—NR6—CH2—CH2-b; a-CH2—CH2—CH2—NR6—CH2-b; or a-CH2—CH2—CH2—CH2—NR6-b; wherein R6 represents hydrogen alkyl or CH2CH2OH; or a pharmaceutically acceptable salt thereof.

    摘要翻译: 本发明涉及能够拮抗兴奋性氨基酸如谷氨酸的作用的新的吲哚-2,3-二酮-3-肟衍生物。 更具体地,本发明的新的吲哚-2,3-二酮-3-肟衍生物可以由通式(I)描述,其中R 3表示“Het”,或式(II)的基团,其中“Het”表示 饱和或不饱和的4至7元单环杂环,R 31,R 32和R 33独立的至少一个表示氢,烷基或羟基烷基,并且R 31,R 32和R 33中的至少一个独立地表示(CH 2) nR34; 其中R34表示羟基,羧基,烷氧基羰基,烯氧基羰基,炔氧基羰基,环烷氧基羰基,环烷基烷氧基羰基,芳氧基羰基,芳烷氧羰基,CONR35R36或“Het”。 其中n为0,1,2或3; 并且R 5表示苯基,萘基,噻吩基或吡啶基,它们都可以被取代。 “A”表示在标记为“a”和“b”的位置与苯并环稠合的5至7个原子的环,由以下二价基团形成:a-NR6-CH2-CH2-b; a-CH2-NR6-CH2-b; a-CH2-CH2-NR6-b; a-NR6-CH2-CH2-H2-b; a-CH2-NR6-CH2-CH2-b; a-CH2-CH2-NR6-CH2-b; a-CH2-CH2-CH2-NR6-b; a-NR6-CH2-CH2-CH2-CH2-b; a-CH 2 -NR 6 -CH 2 -CH 2 -CH 2 -B; a-CH2-CH2-NR6-CH2-CH2-b; a-CH2&mdas

    Indole-2,3-dione-3-oxime derivatives for therapeutic use
    5.
    发明授权
    Indole-2,3-dione-3-oxime derivatives for therapeutic use 失效
    用于治疗用途的吲哚-2,3-二酮-3-肟衍生物

    公开(公告)号:US06239128B1

    公开(公告)日:2001-05-29

    申请号:US09675214

    申请日:2000-09-29

    IPC分类号: A61K3155

    CPC分类号: C07D471/04

    摘要: The present invention relates to the use of indole-2,3-dione-3-oxime derivatives in a method of combating diseases and disorders associated with or mediated by the release of excitatory amino acids.

    摘要翻译: 本发明涉及吲哚-2,3-二酮-3-肟衍生物在抗兴奋性氨基酸释放相关疾病和病症的方法中的应用。

    Method of antagonizing excitatory amino acids by administration of
imidazobenzodiazepine compounds
    6.
    发明授权
    Method of antagonizing excitatory amino acids by administration of imidazobenzodiazepine compounds 失效
    通过施用咪唑并二氮杂化合物拮抗兴奋性氨基酸的方法

    公开(公告)号:US5270306A

    公开(公告)日:1993-12-14

    申请号:US703160

    申请日:1991-05-20

    IPC分类号: A61K31/55 A01N43/62

    CPC分类号: A61K31/55

    摘要: A method of antagonizing the biological effects of an excitatory amino acid of a subject in need of such antagonization comprising the step of administering to said subject an effective amount of a compound having the formula ##STR1## wherein R.sup.3 is hydrogen, C.sub.1-8 -alkyl which may be branched, or cycloalkylmethyl;R.sup.7 and R.sup.8 are independently hydrogen, halogen, CF.sub.3, CN, NO.sub.2, NH.sub.2, C.sub.1-4 -alkyl or C.sub.1-4 -alkoxy; andR.sup.4 is hydrogen and R.sup.5 is hydrogen or C.sub.1-7 -alkyl; or R.sup.4 and R.sup.5 together signify (CH.sub.2).sub.n wherein n is an integer of 2-3.

    摘要翻译: 拮抗需要这种拮抗作用的受试者的兴奋性氨基酸的生物学作用的方法,包括向所述受试者施用有效量的具有下式的化合物(I)的步骤:其中R 3是氢,C1- 可以是支链的8-烷基或环烷基甲基; R 7和R 8独立地是氢,卤素,CF 3,CN,NO 2,NH 2,C 1-4 - 烷基或C 1-4 - 烷氧基; R4为氢,R5为氢或C1-7烷基; 或R 4和R 5一起表示(CH 2)n,其中n是2-3的整数。

    AMPA antagonists and a method of treatment
    7.
    发明授权
    AMPA antagonists and a method of treatment 失效
    AMPA拮抗剂和治疗方法

    公开(公告)号:US5843945A

    公开(公告)日:1998-12-01

    申请号:US951059

    申请日:1997-10-15

    CPC分类号: C07D471/04 C07D487/04

    摘要: The present patent application discloses compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen, alkyl or benzyl; X is O or NOR.sup.2, wherein R.sup.2 is hydrogen, alkyl or benzyl; Y is N--R.sup.4 wherein R.sup.4 is hydrogen, OH or alkyl; n is 0 or 1; R.sup.6 is phenyl, naphthyl, thienyl, pyridyl, all of which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.3, NO.sub.2, amino, alkyl, alkoxy and phenyl; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders. ##STR1##

    摘要翻译: 本专利申请公开了具有式(I)的化合物或其药学上可接受的盐,其中R 1是氢,烷基或苄基; X是O或NOR2,其中R2是氢,烷基或苄基; Y是N-R4,其中R4是氢,OH或烷基; n为0或1; R6是苯基,萘基,噻吩基,吡啶基,它们都可以被选自卤素,CF 3,NO 2,氨基,烷基,烷氧基和苯基的取代基取代一次或多次; A是在标记a和b的位置与苯环稠合的5至7个原子的环。 该化合物可用于治疗脑血管障碍。

    AMPA antagonists and method of treatment therewith
    8.
    发明授权
    AMPA antagonists and method of treatment therewith 失效
    AMPA拮抗剂及其治疗方法

    公开(公告)号:US5780493A

    公开(公告)日:1998-07-14

    申请号:US951821

    申请日:1997-10-16

    CPC分类号: C07D471/04 C07D487/04

    摘要: The present patent application discloses compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen, alkyl or benzyl; X is O or NOR.sup.2, wherein R.sup.2 is hydrogen, alkyl or benzyl; Y is N--R.sup.4 wherein R.sup.4 is hydrogen, OH or alkyl; n is 0 or 1; R.sup.6 is phenyl, naphthyl, thienyl, pyridyl, all of which may be substituted one or more times with substituents selected from the group consisting of halogen; CF.sub.3, NO.sub.2, amino, alkyl, alkoxy and phenyl; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders for example. ##STR1##

    摘要翻译: 本专利申请公开了具有式(I)的化合物或其药学上可接受的盐,其中R 1是氢,烷基或苄基; X是O或NOR2,其中R2是氢,烷基或苄基; Y是N-R4,其中R4是氢,OH或烷基; n为0或1; R6是苯基,萘基,噻吩基,吡啶基,它们都可以被选自卤素的取代基取代一次或多次; CF 3,NO 2,氨基,烷基,烷氧基和苯基; A是在标记a和b的位置与苯环稠合的5至7个原子的环。 该化合物可用于治疗例如脑血管障碍。 (一)

    Indole-2,3-dione-3-oxime derivatives
    9.
    发明授权
    Indole-2,3-dione-3-oxime derivatives 失效
    吲哚-2,3-二酮-3-肟衍生物

    公开(公告)号:US06693111B1

    公开(公告)日:2004-02-17

    申请号:US09584117

    申请日:2000-05-31

    IPC分类号: A61K315375

    CPC分类号: C07D471/04 C07D487/04

    摘要: Indole-2,3-dione-3-oxime derivatives, for instance compounds represented by the formula are capable of antagonizing the effect of excitatory amino acids, such as glutamate. Also disclosed are methods of preparing the compounds, pharmaceutical compositions comprising them, and methods of treatment of disorders or diseases which are responsive to excitatory amino acid receptor antagonists.

    摘要翻译: 吲哚-2,3-二酮-3-肟衍生物,例如由下式表示的化合物能够拮抗兴奋性氨基酸如谷氨酸的作用。 还公开了制备化合物的方法,包含它们的药物组合物,以及治疗对兴奋性氨基酸受体拮抗剂有反应的病症或疾病的方法。

    Indole-derivatives, method of treatment therewith, and pharmaceutical
compositions comprising such compounds
    10.
    发明授权
    Indole-derivatives, method of treatment therewith, and pharmaceutical compositions comprising such compounds 失效
    吲哚衍生物,其治疗方法和包含这些化合物的药物组合物

    公开(公告)号:US5478859A

    公开(公告)日:1995-12-26

    申请号:US259016

    申请日:1994-06-13

    CPC分类号: C07D209/40

    摘要: The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.21 and R.sup.22 each independently are alkyl; andR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12, R.sup.13, and R.sup.14 each independently are hydrogen, halogen, CF.sub.3, CN, or NO.sub.2.The compounds are useful as in vivo active glutamate antagonists.

    摘要翻译: 本专利申请公开了具有式“IMAGE”的化合物或其药学上可接受的盐,其中R 21和R 22各自独立地为烷基; 并且R 1,R 2,R 3,R 4,R 11,R 12,R 13和R 14各自独立地为氢,卤素,CF 3,CN或NO 2。 这些化合物可用作体内活性谷氨酸拮抗剂。